天康生物(002100) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥4,876,888,188.45, representing a 10.53% increase year-over-year[6]. - Net profit attributable to shareholders for Q3 2022 reached ¥355,439,234.76, a significant increase of 181.85% compared to the same period last year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥362,232,096.57, up 183.93% year-over-year[6]. - Basic earnings per share for Q3 2022 were ¥0.26, reflecting a 165.00% increase from ¥0.19 in the same quarter last year[6]. - The company's net profit attributable to shareholders rose to ¥2.48 billion, compared to ¥2.22 billion in the previous year, an increase of approximately 11.7%[27]. - Basic earnings per share for the current period is 0.19, compared to -0.18 in the previous period[33]. - The total comprehensive income attributable to shareholders of the parent company is 245,186,269.12, while the previous period showed a loss of 158,326,403.58[33]. Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥18,963,552,324.99, marking a 10.35% increase from the end of the previous year[6]. - Total assets increased to ¥18.96 billion as of September 30, 2022, compared to ¥17.18 billion at the beginning of the year, reflecting a growth of approximately 10.4%[27]. - The total liabilities decreased to ¥9.31 billion from ¥9.40 billion, a decline of approximately 0.9%[27]. - The equity attributable to shareholders increased to ¥7.89 billion from ¥7.15 billion, reflecting a growth of about 10.3%[27]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥1,833,785,122.11, down 49.47% compared to the same period last year[13]. - The net cash flow from operating activities decreased to 1,833,785,122.11 from 3,629,302,404.17 in the previous period[37]. - The net cash flow from financing activities was ¥1,443,593,555.22, a 192.00% increase, primarily due to increased investments from shareholders[13]. - The net cash flow from financing activities is 1,443,593,555.22, a significant improvement from -1,569,136,550.80 in the previous period[40]. - The total cash and cash equivalents at the end of the period is 5,811,695,832.70, up from 2,767,644,090.16 in the previous period[40]. Investments and Shareholding - The company reported a total of 283,929,184 shares held by its largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd., representing a significant portion of ownership[17]. - Xinjiang Tianbang Hongkang Venture Capital Partnership holds 62,580,733 shares, accounting for 4.62% of the total shares[17]. - The company has initiated a mixed-ownership reform plan for Tiankang Pharmaceutical (Suzhou) Co., Ltd., approved by the board on June 1, 2022, to attract external strategic investors and employee shareholding[20]. - The share price for the external strategic investment in Tiankang Pharmaceutical was set at 15.81 yuan per unit of registered capital during the public solicitation process[21]. - As of September 25, 2022, all new shareholders of Tiankang Pharmaceutical have completed their capital contributions[21]. - The company is actively expanding its market presence through strategic partnerships and investments in Tiankang Pharmaceutical[20]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder having no related party relationships with others[17]. - The company is focused on enhancing its capital structure through the introduction of new investors and employee ownership initiatives[20]. Research and Development - Research and development expenses increased by 72.71% to ¥50,492,134.33, indicating a focus on innovation[13]. - Research and development expenses for the quarter were ¥122.35 million, up from ¥103.20 million, indicating an increase of about 18.5%[30]. Other Financial Metrics - The company's cash and cash equivalents increased to ¥5.92 billion from ¥3.42 billion, marking a significant growth of about 73.1%[24]. - Inventory decreased to ¥3.93 billion from ¥5.23 billion, a reduction of approximately 24.8%[24]. - Long-term borrowings increased to ¥2.89 billion from ¥1.96 billion, reflecting a growth of about 47.3%[27]. - The company's long-term borrowings rose by 47.06% to ¥2,888,269,363.22, reflecting adjustments in loan structure[13]. - The total profit for the current period is 217,953,683.97, compared to a loss of 57,757,472.82 in the previous period[33]. - The net profit attributable to shareholders of the parent company is 257,958,881.22, while the previous period showed a loss of 192,859,153.56[33]. - The net cash flow from investing activities is -777,460,915.19, compared to -1,242,949,423.18 in the previous period[40]. - The company reported a decrease in other comprehensive income, with a net amount of -12,772,612.10 compared to 34,532,749.98 in the previous period[33].